PHASE III AXIS TRIAL OF AXITINIB VERSUS SORAFENIB IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA: ASIAN SUBGROUP ANALYSIS

被引：0
|
作者：
Uemura, H. [1 ]
Ou, Y. -C. [2 ]
Lim, H. Y. [3 ]
Tomita, Y. [4 ]
Ueda, T. [5 ]
Menon, H. [6 ]
Chung, J. [7 ]
Guo, J. [8 ]
Tarazi, J. [9 ]
Kim, S. [9 ]
Naito, S. [10 ]
Akaza, H. [11 ]
机构：
[1] Kinki Univ, Sch Med, Dept Urol, Osaka 589, Japan
[2] Taichung Vet Gen Hosp, Dept Surg, Taichung, Taiwan
[3] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Dept Hematol Oncol, Seoul, South Korea
[4] Yamagata Univ, Fac Med, Dept Urol, Yamagata 990, Japan
[5] Chiba Canc Ctr, Dept Urol, Chiba 2608717, Japan
[6] Tata Mem Hosp, Dept Med Oncol, Bombay 400012, Maharashtra, India
[7] Natl Canc Ctr, Urol Oncol Clin, Gyeonggi Do, South Korea
[8] Peking Univ, Canc Hosp, Dept Renal Canc & Melanoma, Beijing 100871, Peoples R China
[9] Pfizer Oncol, La Jolla, CA USA
[10] Kyushu Univ, Grad Sch Med Sci, Dept Urol, Fukuoka 812, Japan
[11] Univ Tokyo, Res Ctr Adv Sci & Technol, Tokyo, Japan
来源：
ANNALS OF ONCOLOGY | 2012年 / 23卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：6 / 6
页数：1
相关论文
共 50 条
  • [1] First-line axitinib versus sorafenib in Asian patients with metastatic renal cell carcinoma (mRCC): Subgroup analysis of data from a phase III trial
    Sheng, X.
    Bi, F.
    Ren, X.
    Cheng, Y.
    Wang, J.
    Rosbrook, B.
    Jiang, M.
    Guo, J.
    ANNALS OF ONCOLOGY, 2017, 28 : 82 - 82
  • [2] First-line axitinib versus sorafenib in Asian patients with metastatic renal cell carcinoma: exploratory subgroup analyses of Phase III data
    Sheng, Xinan
    Bi, Feng
    Ren, Xiubao
    Cheng, Ying
    Wang, Jinwan
    Rosbrook, Brad
    Jiang, Ming
    Guo, Jun
    FUTURE ONCOLOGY, 2019, 15 (01) : 3267 - 3278
  • [3] Efficacy and Safety of Axitinib Versus Sorafenib in Metastatic Renal Cell Carcinoma: Subgroup Analysis of Japanese Patients from the Global Randomized Phase 3 AXIS Trial
    Ueda, Takeshi
    Uemura, Hirotsugu
    Tomita, Yoshihiko
    Tsukamoto, Taiji
    Kanayama, Hiroomi
    Shinohara, Nobuo
    Tarazi, Jamal
    Chen, Connie
    Kim, Sinil
    Ozono, Seiichiro
    Naito, Seiji
    Akaza, Hideyuki
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2013, 43 (06) : 616 - 628
  • [4] Phase III AXIS trial of axitinib versus sorafenib in metastatic renal cell carcinoma: Updated results among cytokine-treated patients
    Michaelson, M. Dror
    Rini, Brian I.
    Escudier, Bernard J.
    Clark, Joseph
    Redman, Bruce
    Tarazi, Jamal Christo
    Rosbrook, Brad
    Kim, Sinil
    Motzer, Robert John
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [5] Patient-reported outcomes for axitinib vs sorafenib in metastatic renal cell carcinoma: phase III (AXIS) trial
    Cella, D.
    Escudier, B.
    Rini, B.
    Chen, C.
    Bhattacharyya, H.
    Tarazi, J.
    Rosbrook, B.
    Kim, S.
    Motzer, R.
    BRITISH JOURNAL OF CANCER, 2013, 108 (08) : 1571 - 1578
  • [6] Patient-reported outcomes for axitinib vs sorafenib in metastatic renal cell carcinoma: phase III (AXIS) trial
    D Cella
    B Escudier
    B Rini
    C Chen
    H Bhattacharyya
    J Tarazi
    B Rosbrook
    S Kim
    R Motzer
    British Journal of Cancer, 2013, 108 : 1571 - 1578
  • [7] Axitinib versus sorafenib as second-line therapy for metastatic renal cell carcinoma (mRCC): Results of phase III AXIS trial.
    Rini, B. I.
    Escudier, B.
    Tomczak, P.
    Kaprin, A.
    Hutson, T. E.
    Szczylik, C.
    Tarazi, J. C.
    Rosbrook, B.
    Kim, S.
    Motzer, R. J.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [8] Hypertension among patients with renal cell carcinoma receiving axitinib or sorafenib: analysis from the randomized phase III AXIS trial
    Rini, Brian I.
    Quinn, David I.
    Baum, Michael
    Wood, Laura S.
    Tarazi, Jamal
    Rosbrook, Brad
    Arruda, Lillian Shahied
    Cisar, Laura
    Roberts, W. Gregory
    Kim, Sinil
    Motzer, Robert J.
    TARGETED ONCOLOGY, 2015, 10 (01) : 45 - 53
  • [9] Hypertension among patients with renal cell carcinoma receiving axitinib or sorafenib: analysis from the randomized phase III AXIS trial
    Brian I. Rini
    David I. Quinn
    Michael Baum
    Laura S. Wood
    Jamal Tarazi
    Brad Rosbrook
    Lillian Shahied Arruda
    Laura Cisar
    W. Gregory Roberts
    Sinil Kim
    Robert J. Motzer
    Targeted Oncology, 2015, 10 : 45 - 53
  • [10] Adjuvant axitinib in Asian vs non-Asian patients with metastatic renal cell carcinoma (mRCC): ATLAS trial subgroup analysis
    Ng, C. F.
    Kwon, T. G.
    Eto, M.
    Miyake, H.
    Seo, S. I.
    Byun, S-S.
    Lee, J. L.
    Rosbrook, B.
    Grande, E.
    Gross-Goupil, M.
    Quinn, D. I.
    ANNALS OF ONCOLOGY, 2019, 30
12345